KR0158436B1 - 개선된 수막염균성 폴리사카라이드 결합체 백신 - Google Patents

개선된 수막염균성 폴리사카라이드 결합체 백신 Download PDF

Info

Publication number
KR0158436B1
KR0158436B1 KR1019920701403A KR920701403A KR0158436B1 KR 0158436 B1 KR0158436 B1 KR 0158436B1 KR 1019920701403 A KR1019920701403 A KR 1019920701403A KR 920701403 A KR920701403 A KR 920701403A KR 0158436 B1 KR0158436 B1 KR 0158436B1
Authority
KR
South Korea
Prior art keywords
group
polysaccharide
butanoyl
acyl group
gbmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920701403A
Other languages
English (en)
Korean (ko)
Inventor
제이. 제닝스 해롤드
미천 프랜시스
Original Assignee
피에르 오. 페론
내셔날 리서취 카운설 오브 캐나다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 오. 페론, 내셔날 리서취 카운설 오브 캐나다 filed Critical 피에르 오. 페론
Application granted granted Critical
Publication of KR0158436B1 publication Critical patent/KR0158436B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1019920701403A 1989-12-14 1990-12-13 개선된 수막염균성 폴리사카라이드 결합체 백신 Expired - Fee Related KR0158436B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
US7/448,195 1989-12-14
PCT/CA1990/000437 WO1991008772A1 (en) 1989-12-14 1990-12-13 Improved meningococcal polysaccharide conjugate vaccine

Publications (1)

Publication Number Publication Date
KR0158436B1 true KR0158436B1 (ko) 1998-12-01

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701403A Expired - Fee Related KR0158436B1 (ko) 1989-12-14 1990-12-13 개선된 수막염균성 폴리사카라이드 결합체 백신

Country Status (30)

Country Link
US (3) US5576002A (https=)
EP (1) EP0504202B1 (https=)
JP (1) JP2637845B2 (https=)
KR (1) KR0158436B1 (https=)
CN (4) CN1049223C (https=)
AR (1) AR243934A1 (https=)
AT (1) ATE121947T1 (https=)
AU (1) AU641715B2 (https=)
BR (1) BR9007917A (https=)
CA (1) CA2071811C (https=)
CZ (1) CZ283530B6 (https=)
DE (1) DE69019164T2 (https=)
DK (1) DK0504202T3 (https=)
ES (1) ES2071288T3 (https=)
FI (2) FI104539B (https=)
HR (1) HRP920872A2 (https=)
HU (2) HU9201966D0 (https=)
IE (1) IE68414B1 (https=)
IL (1) IL96676A (https=)
IN (1) IN171747B (https=)
NO (2) NO305275B1 (https=)
NZ (1) NZ236471A (https=)
PH (1) PH30305A (https=)
PL (2) PL166035B1 (https=)
RO (1) RO111416B1 (https=)
RU (1) RU2105568C1 (https=)
SI (1) SI20008B (https=)
WO (1) WO1991008772A1 (https=)
YU (1) YU24391A (https=)
ZA (1) ZA9010065B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
DE69019164T2 (de) * 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.
ES2160601T3 (es) * 1992-09-24 2001-11-16 Brigham & Womens Hospital Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
CA2301942C (en) * 1997-08-27 2011-05-31 Chiron Corporation Molecular mimetics of meningococcal b epitopes
WO1999032653A1 (en) 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
JP2004505885A (ja) * 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
PT1777236T (pt) * 2002-03-26 2017-02-13 Glaxosmithkline Biologicals Sa Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7595307B2 (en) 2004-06-23 2009-09-29 Children's Hospital And Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
WO2010083477A2 (en) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
DE69019164T2 (de) * 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Also Published As

Publication number Publication date
NO922316D0 (no) 1992-06-12
ZA9010065B (en) 1992-02-26
CN1036522C (zh) 1997-11-26
ES2071288T3 (es) 1995-06-16
PH30305A (en) 1997-02-20
IE904513A1 (en) 1991-06-19
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
HUT64480A (en) 1994-01-28
AR243934A1 (es) 1993-09-30
SI20008A (sl) 2000-02-29
AU6898791A (en) 1991-07-18
IL96676A0 (en) 1991-09-16
NZ236471A (en) 1992-10-28
IL96676A (en) 1996-09-12
CA2071811C (en) 2003-11-04
NO305275B1 (no) 1999-05-03
PL288271A1 (en) 1991-12-16
US5902586A (en) 1999-05-11
CN1036504C (zh) 1997-11-26
DK0504202T3 (da) 1995-10-02
NO973311L (no) 1992-08-14
AU641715B2 (en) 1993-09-30
JP2637845B2 (ja) 1997-08-06
HU218146B (hu) 2000-06-28
IN171747B (https=) 1992-12-26
NO307835B1 (no) 2000-06-05
DE69019164T2 (de) 1995-09-07
WO1991008772A1 (en) 1991-06-27
BR9007917A (pt) 1992-10-20
CZ283530B6 (cs) 1998-04-15
PL166035B1 (pl) 1995-03-31
CN1100656A (zh) 1995-03-29
FI922737A0 (fi) 1992-06-12
PL166659B1 (pl) 1995-06-30
ATE121947T1 (de) 1995-05-15
RU2105568C1 (ru) 1998-02-27
HRP920872A2 (en) 1997-06-30
EP0504202B1 (en) 1995-05-03
YU24391A (sh) 1995-12-04
IE68414B1 (en) 1996-06-12
FI19991917L (fi) 1999-09-09
FI104539B (fi) 2000-02-29
CA2071811A1 (en) 1991-06-15
HU9201966D0 (en) 1992-10-28
CN1055541A (zh) 1991-10-23
FI19991917A7 (fi) 1999-09-09
CZ628490A3 (en) 1997-12-17
RO111416B1 (ro) 1996-10-31
NO922316L (no) 1992-08-14
CN1072506C (zh) 2001-10-10
JPH05505392A (ja) 1993-08-12
US5576002A (en) 1996-11-19
DE69019164D1 (de) 1995-06-08
EP0504202A1 (en) 1992-09-23
CN1096516A (zh) 1994-12-21
CN1100428A (zh) 1995-03-22
US5683699A (en) 1997-11-04
CN1049223C (zh) 2000-02-09

Similar Documents

Publication Publication Date Title
KR0158436B1 (ko) 개선된 수막염균성 폴리사카라이드 결합체 백신
JP4656728B2 (ja) ブドウ球菌抗原及びワクチン
US7291343B2 (en) Enterococcus antigens and vaccines
JP6335102B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
AU706053B2 (en) Modified meningococcal polysaccharide conjugate vaccines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20080725

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090805

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090805